NEW YORK – The US Food and Drug Administration on Monday issued Emergency Use Authorization to Euroimmun's EuroRealTime SARS-CoV-2 molecular assay COVID-19.
The PCR-based test is for the qualitative detection of nucleic acid from SARS-CoV-2 in upper respiratory specimens, including nasal, nasopharyngeal, mid-turbinate, and oropharyngeal swabs, as well as bronchioalveolar lavage from patients who are suspected of having COVID-19.